9 terminated. 9 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Terminated 9 |
| Phase 1 | 5 | Terminated 5 |
Follow Peritoneal Cancer: new trials by email Literature Review of Peritoneal Cancer trials Research Report on Peritoneal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy Allocetra-OTS, Nivolumab, Tislelizumab - Solid Tumor, Peritoneal Metastases | Phase 1 / Phase 2 | Terminated | Enlivex Therapeutics RDO Ltd. | 14 | 2022-11-15 | 2024-04-17 |
| A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±) ELU001 - Ovarian Cancer, Ovarian Neoplasms | Phase 1 / Phase 2 | Terminated | Elucida Oncology | 79 | 2021-09-13 | 2024-08-07 |
| T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer Ipilimumab, Cyclophosphamid, Fludarabine Phosphate - Metastatic Ovarian Cancer, Metastatic Fallopian Tube Cancer | Phase 1 / Phase 2 | Terminated | Inge Marie Svane | 6 | 2021-04-22 | 2025-08-12 |
| Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction Cisplatin, Paclitaxel - Ovarian Cancer, Peritoneal Cancer | Phase 1 / Phase 2 | Terminated | University Health Network, Toronto | 1 | 2010-02-01 | 2019-02-15 |
| Abraxane/Bevacizumab Abraxane, Bevacizumab - Ovarian Cancer, Peritoneal Cancer | Phase 2 | Terminated | OHSU Knight Cancer Institute | 5 | 2010-01-01 | 2013-07-26 |
| Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer Vorinostat, Carboplatin, Gemcitabine - Ovarian Cancer, Fallopian Tube Cancer | Phase 1 / Phase 2 | Terminated | Dana-Farber Cancer Institute | 15 | 2009-06-01 | 2018-09-10 |
| Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer Bevacizumab, Carboplatin, Paclitaxel - Ovarian Cancer, Peritoneal Cancer | Phase 2 | Terminated | UConn Health | 5 | 2006-10-01 | 2018-03-08 |
| Letrozole in Patients With Ovarian Tumors Letrozole - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Terminated | M.D. Anderson Cancer Center | 16 | 2003-09-01 | 2012-04-18 |
| Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer Gemzar and Alimta - Ovarian Cancer, Peritoneal Cancer | Phase 2 | Terminated | Eli Lilly and Company | 2006-09-15 |
Ovarian Neoplasms (8) · Fallopian Tube Neoplasms (6) · Carcinoma (1) · Carcinoma, Endometrioid (1) · Carcinoma, Ovarian Epithelial (1) · Endometrial Neoplasms (1) · Intestinal Obstruction (1) · Krukenberg Tumor (1) · Neoplasms (1) · Ovarian Diseases (1) · Recurrence (1) · Uterine Diseases (1)
Adnexal Diseases (8) · Endocrine Gland Neoplasms (8) · Endocrine System Diseases (8) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Genital Diseases (8) · Genital Diseases, Female (8) · Genital Neoplasms, Female (8) · Gonadal Disorders (8) · Neoplasms by Site (8) · Urogenital Diseases (8) · Urogenital Neoplasms (8) · Neoplasms (7) · Ovarian Diseases (7) · Fallopian Tube Diseases (6)
Bevacizumab (2) · Carboplatin (2) · Gemcitabine (2) · Nivolumab (2) · Paclitaxel (2) · Albumin-Bound Paclitaxel (1) · Cisplatin (1) · Cyclophosphamide (1) · Ipilimumab (1) · Letrozole (1) · Pemetrexed (1) · Taxes (1) · Vorinostat (1) · fludarabine phosphate (1) · relatlimab (1)
Dana-Farber Cancer Institute (1) · Eli Lilly and Company (1) · Elucida Oncology (1) · Enlivex Therapeutics RDO Ltd. (1) · Inge Marie Svane (1) · M.D. Anderson Cancer Center (1) · OHSU Knight Cancer Institute (1) · UConn Health (1) · University Health Network, Toronto (1)
United States (6) · Canada (1) · Denmark (1) · Israel (1) · Spain (1)
Amit Oza (1) · Carolyn Runowicz, MD (1) · Inge Marie Svane, Prof., M.D. (1) · John J. Kavanagh, MD (1) · Nicole Chau (1) · Roni Shapira, MD (1) · Tanja Pejovic, MD, PhD (1) · Tine J Monberg, M.D. (1) · Ursula A. Matulonis, MD (1)